The mammalian target of rapamycin (mTOR) kinase integrates cues from nutrients and growth factors, acting as a nexus point for cellular signals to control growth, metabolism, and longevity. Deregulation of either of mTOR's two complexes, mTORC1 or mTORC2, leads to diseases of metabolism, including cancer and diabetes. In this issue's Select, insights into the extent of mTOR's oncogenic capabilities come to light, and it appears that an old drug (rapamycin) has some new tricks in vivo. © 2012 Elsevier Inc.
Hosking, R. (2012). mTOR: The master regulator. Cell, 149(5), 955–957. https://doi.org/10.1016/j.cell.2012.05.011